What’s Going To Happen With Tempus AI Stock Soon?
Today’s big story: Could Anthropic Stock Fall 25%?
Tempus AI (TEM) stock closed at $63.62 on November 18, 2026, down from its one-year high close of $85.08 on September 28. Management has also agreed to buy Personalis, a cancer-testing company that it says runs its tests at a loss. That deal goes to a Personalis shareholder vote on November 30, and Tempus AI reports results again in February. Below are the events most likely to move Tempus AI stock over the next six months.
| What to watch | When | Which way it cuts |
|---|---|---|
| Personalis shareholders vote on Tempus AI’s purchase, with closing expected in the fourth quarter of 2026 | November 30, 2026 | Against the stock |
| Higher prices per cancer test take effect | beginning in 2027 | In its favor |
| Guardant Health reports fiscal Q4 2026 results, a read on demand for the kind of cancer tests Tempus AI also sells | February 19, 2027 | Either way |
| Tempus AI reports fiscal Q4 2026 results, closing out its 2026 revenue guide | February 2027 | Either way |

A Vote On Buying Personalis
Personalis shareholders will vote on the transaction on November 30, 2026. Tempus AI expects the deal to close in the fourth quarter of 2026, according to its latest quarterly filing. The company plans to pay for the deal in its Class A stock. It may choose to pay up to 50% of the price in cash instead. Tempus AI already sells a Personalis test that monitors patients for cancer returning after treatment.
The catch is cost. Management said on the November 2 call that Personalis loses money on these tests, and that Tempus AI would absorb some of those losses once the deal closes. Tempus AI still reports a net loss. Management expects roughly $65 million of adjusted EBITDA, its own profit measure, for 2026, the same as in July. Even after taking on those losses, it expects that measure to keep improving in 2027.
Tempus AI expects only about $65 million of adjusted EBITDA for 2026, and Personalis will add its losses on top. If much of your savings sits in this one stock, a drop around the November 30 vote could hit you hard. When the market has fallen, the Trefis High Quality (HQ) Portfolio has lost about 81 cents for every $1 its benchmark lost, on average. See the HQ record.
Higher Prices For Tempus AI’s Cancer Tests
Tempus AI expects to be paid more per cancer test starting in 2027. Management said on the July 30, 2026 call that the higher price equates to roughly $85 million a year. That compares with $1,509 million of revenue over the twelve months to September 2026. On the November 2 call, the 2027 uplift in oncology prices was put at about $80 million, a little below the July figure.
Tempus AI’s cancer testing is already growing. Oncology test volumes rose 32% in the third quarter of 2026 from a year earlier, management said. Unlike the losses Personalis brings, this growth counts in the stock’s favor.
Tempus AI’s February Report
Tempus AI is expected to report fiscal Q4 2026 results in February 2027. That report will include hereditary cancer testing, which brought in $111 million in the third quarter. Management said unit growth in that business returned to low double digits in September and October. It also called any broader market headwind small next to the many eligible people who are still untested. So the February report will show whether that pickup held up.
Could You Hold Tempus AI Through These Dates?
Tempus AI shareholders have sat through steep declines before. The stock’s largest fall over the past year was 46.7%, dropping from a close on November 28, 2025 to a close on July 29, 2026.
If a repeat of that fall would push you to sell, your position is too large to hold through a deal vote, a pricing change and a February report. A stake you could watch nearly halve and still keep is one you could carry through these dates. Tempus AI’s February 2027 report will measure full-year 2026 revenue against management’s guide of $1.60 billion to $1.605 billion.
A stock that has dropped this far within one year is difficult to own with an easy mind. Growing your money matters, but so does the ability to sleep while it grows.
What If You Could Grow Wealth And Still Sleep At Night?
Tempus AI is 25% below its highest close of the past year. How has that felt? The Trefis Income Solution pays a dividend yield about 3x the S&P 500’s, and it lost less than the S&P 500 in all 9 big selloffs since 2018.
Spot an error or want more like this? Tell us in 10 seconds.